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Objectives: To compare the efficacy and safety of insulin glulisine over regular insulin in patients with type 2 diabetes and severe renal
insufficiency.
Subjects:Our study included 18 patients with type 2 diabetes and a mean (range) estimated glomerular filtration rate of 13.2 mL/min-
ute/1.73 m2 (5.8-27.6), which corresponds to stage 4-5 chronic kidney disease.
Design: After titration of doses, regular insulin was administered thrice daily on Day 1, along with continuous glucose monitoring for
24 h starting at 7 AM. Exactly equal doses of insulin glulisine were administered on Day 2. Area under the curve (AUC) for blood glucose
level variation after breakfast (AUC-B 0-4), lunch (AUC-L 0-6), and dinner (AUC-D 0-6) were evaluated.
Results: AUC-B 0-4 and AUC-D 0-6 were significantly lower with insulin glulisine than with regular insulin (AUC-B 0-4: 3.3 6 4.7 vs.
6.2 6 5.4 3 102 mmol/L$minute, respectively, P 5 .028; AUC-D 0-6: 1.8 6 7.3 vs. 6.5 6 6.2 3 102 mmol/L$minute, respectively,
P 5 .023). In contrast, AUC-L 0-6 was higher with insulin glulisine than with regular insulin (AUC-L 0-6: 7.6 6 6.4 vs.
4.2 6 8.7 3 102 mmol/L$minute, respectively, P 5 .099), suggesting a prolonged hypoglycemic action of regular insulin after lunch.
Conclusions: Insulin glulisine effectively suppressed postprandial hyperglycemia, whereas regular insulin caused a prolonged hypo-
glycemic action. These findings support the effectiveness and safety of insulin glulisine in patients with type 2 diabetes and severe renal
insufficiency.
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Introduction prognosis in patients with diabetes and advanced com-
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of diabetic retinopathy and nephropathy.1,2 In contrast, the
significance of strict glycemic control in the protection of
patients with diabetes against cardiovascular event is
controversial.3-5 Moreover, it is a matter of debate whether
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Open access under CC BY-NC-ND license.plications such as end-stage renal disease. We previously
reported that poor glycemic controlwas an independent pre-
dictor of poor prognosis in patients with diabetes on hemo-
dialysis.6,7 Interestingly, recent large observational cohort
studies have demonstrated that the association between
glycemic control represented by glycated hemoglobin
(HbA1c) levels and mortality could have U- or J-shaped
curves in patients with diabetes on hemodialysis8,9 or with
stage 3-4 chronic kidney disease (CKD).10 That is, HbA1c
levels .8.0% (64 mmol/mol) or ,6.0% (42 mmol/mol)
are significantly correlated with higher mortality. These
findings suggest that a certain level of glycemic control is
necessary, but avoidance of hypoglycemia is also imperative.
The glucose and insulin metabolism in patients with
diabetes and advanced stages of CKD is complex. Uremia-
induced insulin resistance and secondary hyperparathyroid-
ism–associated impairment of insulin secretion can result in
hyperglycemia. On the other hand, decreased renal gluco-
neogenesis and decreased renal insulin clearance provoke
harmful hypoglycemia.11 Therefore, life-threatening hypo-
glycemia can occur more frequently in the presence of se-
vere renal insufficiency, as emphasized in recent clinical
trials.3-5 In fact, a large national cohort study clearly
showed that the presence of CKD in patients with
diabetes is a significant risk factor for severe hypoglycemia.12129
Figure 1. Outline of the study protocol. After admission, all
oral antidiabetic agents were stopped in eligible patients,
and regular insulin injections were administered thrice daily.
A minimum of 7 days were allowed for washout of oral med-
icine and titration of regular insulin. Blood glucosemonitoring
was started by continuous glucose monitoring (CGM) after
titration of regular insulin doses. The next day (Day 1), insulin
dose injected 30 minutes before each meal was noted. Sub-
sequently, the exact same dose of insulin glulisine was in-
jected just before each meal (Day 2).
URATA ET AL130Oral antidiabetic agents (OADs) have a central role in
glycemic management in patients with diabetes. However,
once renal insufficiency becomes obvious, most OADs
require a dose adjustment or discontinuation because the
accumulation of the parent drugs or active metabolites re-
sults in adverse events such as prolonged hypoglycemia.13
Therefore, insulin is the first-line therapy recommended
in patients with diabetes and severe renal insufficiency. A
recent report suggests that rapid-acting insulin analogs are
safer than regular insulin for avoiding interprandial hypo-
glycemia in patients treated with multiple injections of in-
sulin.14 Indeed, injected regular insulin is associated with a
slow onset of action, a peak effect at 3 hours, and a pro-
longed duration of action. On the other hand, 3 types of
rapid-acting insulin analogs are available: lispro, aspart,
and glulisine. Each has a rapid onset of action (within 30-
60 minutes) and a peak effect within 2 hours. In addition,
insulin glulisine has been reported to be characterized by
a faster onset of action than insulin lispro and insulin as-
part.15,16 Rapid-acting insulin analogs are theoretically
considered better than regular insulin in patients with se-
vere renal insufficiency because these patients are suscepti-
ble to hypoglycemia. However, data that compare insulin
regimens for finding which regimen is better under condi-
tions of severe renal insufficiency are few.
Therefore, using continuous glucose monitor (CGM),
we conducted this study to compare the efficacies of regular
insulin and insulin glulisine in patients with diabetes and se-
vere renal insufficiency. We focused on the efficacy (post-
prandial hyperglycemia and glycemic variation) and safety
(hypoglycemia) of the 2 types of insulin.Methods
Subjects
We recruited patients with type 2 diabetes and severe renal
insufficiency from among the patients admitted to our dia-
betes center atOsakaCityUniversityHospital betweenApril
2010 and March 2012. The estimated glomerular filtration
(eGFR)was calculated as per guidelines proposed by the Jap-
anese Society of Nephrology.17 Patients with stage 4-5 CKD
(eGFR ,30 mL/minute/1.73 m2) were included in our
study (Osaka Diabetes Mellitus and Kidney Diseases study:
Diamond study). Patients with any evidence of nondiabetic
renal disease, severe hepatic dysfunction, malignant tumors,
and untreated diabetic retinopathy were excluded. Patients
undergoing hemodialysis were also excluded. The study
was conducted according to the tenets of the declaration of
Helsinki, and its protocol was approved by the local ethics
committee (Registration No. 1739). After explanation of
the study objectives, all patients gave their written informed
consent for participation.
Study Design
The protocol for the present study is outlined in
Figure 1. After enrollment, we discontinued OADs inall eligible patients and administered subcutaneous injec-
tions of regular insulin 3 times a day. Each patient’s
blood glucose (BG) level was measured before each
meal and at bedtime using a BG self-monitoring device
(Medisafe Mini; Terumo, Tokyo, Japan). In cases where
it was necessary to titrate the insulin dose, a 2-hour post-
prandial BG level was also arbitrarily checked. The target
preprandial and postprandial BG level ranges were 5.6 to
6.7 mmol/L and 6.7 to 9.4 mmol/L, respectively. Special
emphasis was placed on avoiding hypoglycemic episodes.
After administration of correctional doses of regular in-
sulin, BG levels were monitored for a day using a CGM
device (CGMS-gold: Medtronic Minimed, Northridge,
CA). The next day (Day 1), the determined doses of reg-
ular insulin were subcutaneously injected 30 minutes
before each meal, and BG levels were continuously re-
corded for 24 hours from 7:00 AM. On the following
day (Day 2), exact equivalent doses of insulin glulisine
were administered just before each meal, and glycemic
control was assessed in a similar fashion. For example,
if regular insulin was injected at 6, 4, and 8 units 30 mi-
nutes before each meal, respectively, insulin glulisine was
also injected at 6, 4, and 8 units just before each meal,
respectively.
We evaluated the following values using CGM data in
Day 1 and Day 2: (a) BG level (mean6 standard deviation);
(b) mean amplitude of glycemic excursions18; and (c) area
under the curve (AUC) for BG levels within 4 hours after
breakfast (AUC-B 0-4), for BG levels within 6 hours after
lunch (AUC-L 0-6), and for BG levels within 6 hours after
dinner (AUC-D 0-6), after calculation of variations at every
5 minutes from baseline BG levels for each meal.Statistical Analyses
Data were expressed as mean 6 standard deviation or
median (interquartile range) as appropriate. The paired
Table 1. Clinical Characteristics in Patients With Type 2
Diabetes and Severe Renal Insufficiency
Age (y) 64.8 6 9.2
Sex (male/female) 15/3
Body mass index (kg/m2) 26.0 6 3.8
Duration of diabetes (y) 18.9 6 9.7
Fasting plasma glucose (mmol/L) 6.5 6 2.2
HbA1c, % (mmol/mol) 7.2 6 1.4 (55 6 15)
Glycated albumin (%) 19.2 6 5.4
sCPR (nmol/L) 1.3 6 0.9
Creatinine (mmol/L) 380.1 6 123.8
eGFR (mL/minute/1.73 m2) 13.2 6 6.3
eGFR, estimated glomerular filtration rate; sCPR, serumC peptide
immunoreactivity.
Data are mean 6 SD.
GLULISINE IN SEVERE RENAL INSUFFICIENCY 131t-test was used to compare values between the 2 insulin reg-
imens. P , .05 was considered statistically significant.Results
Clinical characteristics of all patients are shown in
Table 1. We finally included a total of 18 patients, with 8
patients receiving basal insulin injections to achieve fasting
BG levels in the range of 5.6 to 6.7 mmol/L (7 patients with
glargine and 1 patient with neutral protamine Hargedorn
insulin). After adjusting the dose of regular insulin, the
amount administered before each meal (breakfast, lunch,
and dinner) was 9.26 3.7, 7.36 3.9, and 8.26 3.7 units,
respectively. With regard to episodes of hypoglycemia
(defined as BG level ,3.9 mmol/L), only 1 instance
(3.8 mmol/L at 2:35 AM in Day 1) was recorded without
any hypoglycemic symptoms during the CGM period.
Fluctuations in the 24-hour BG levels on Day 1 (regular in-
sulin) and Day2 (glulisine) as evaluated by CGM are shown
in Figure 2. The mean 24-hour BG levels in Day 1 and DayFigure 2. Glucose levels during 24 hours of treatment with regular
lines indicate mean and standard deviation (SD), respectively, dur
lines indicate mean 6 SD, respectively, during treatment with insu2 were 9.36 3.6 and 8.96 2.9 mmol/L, respectively. This
difference was statistically significant (P , .0001). Mean
amplitude of glycemic excursions on Day 2
(4.9 6 2.1 mmol/L) tended to be lower than that on
Day1 (5.6 6 3.0 mmol/L), although not to a significant
extent (P 5 .146).
To compare the predominant effect of each regimen on
glycemic control, we focused on postprandial variation of
BG levels. Figure 3 shows the amount of changes from
baseline BG level at each meal when treated with either
regular insulin or insulin glulisine. AUC-B 0-4 and
AUC-D 0-6 were lower with insulin glulisine (Day 2)
than with regular insulin (Day 1). In contrast, AUC-L 0-
6with insulin glulisinewas higher thanwith regular insulin.
Next, we compared the AUC values for both treatments
(Fig. 4). Insulin glulisine showed a significantly greater sup-
pression of AUC-B 0-4 and AUC-D 0-6 than regular insu-
lin (AUC-B 0-4: 3.3 6 4.7 vs. 6.2 6 5.4 3 102 mmol/
L$minute, respectively, P 5 .028; AUC-D 0-6: 1.8 6 7.3
vs. 6.5 6 6.2 3 102 mmol/L$minute, respectively,
P 5 .023). On the other hand, AUC-L 0-6 tended to be
higher with insulin glulisine than with regular insulin, but
the difference was not statistically significant (AUC-L 0-
6: 7.66 6.4 vs. 4.26 8.73 102 mmol/L$minute, respec-
tively, P 5 .099).
Discussion
To our knowledge, this is the first report to demonstrate
direct comparison of regular insulin with the rapid-acting
insulin analog, insulin glulisine, in patients with diabetes
and severe renal insufficiency, on the basis of detailed eval-
uation of 24-hour monitoring of BG levels using CGM.
We found that compared with regular insulin, insulin glu-
lisine, at the same dose, powerfully suppressed postprandial
hyperglycemia after breakfast and dinner. On the otherinsulin (Day 1) or insulin glulisine (Day 2). Gray bold and thin
ing treatment with regular insulin (Day 1). Black bold and thin
lin glulisine (Day 2).
Figure 3. Postprandial variation of blood glucose (BG) level from the baseline for each meal during regular insulin treatment (Day
1) or insulin glulisine treatment (Day 2). The amount of changes from baseline BG levels for each meal during treatment with reg-
ular insulin (Day 1: left panel) and insulin glulisine (Day 2: right panel). Area under the curve (AUC)-B 0-4 and AUC-D 0-6 were
lower during insulin glulisine treatment (Day 2) than during regular insulin treatment (Day 1). Conversely, the AUC-L 0-6 was
higher during insulin glulisine treatment than during regular insulin treatments.
URATA ET AL132hand, regular insulin injected before breakfast showed pro-
longed hypoglycemic action after lunch. These findings
suggest that insulin glulisine is much better than regular in-
sulin with regard to efficacy and safety, even under condi-
tions of renal insufficiency.
Because the kidney plays a critical role for glucose meta-
bolism, the progression of renal insufficiency in diabetes pa-
tients may lead to serious complications. Among them,
hypoglycemia is serious and potentially life threatening.
Endogenous insulin secreted from the pancreatic beta cells
reaches the liver via the portal vein. Approximately 40% to
50% of insulin is degraded when it passes through the liver.Figure 4.Comparison of are under the curve (AUC) for blood gluco
(AUC-D 0-6) during regular insulin treatment (Day 1) and insulin glul
with insulin glulisine than with regular insulin (AUC-B 0-4: 3.3 6 4.7
AUC-D 0-6: 1.86 7.3 vs. 6.56 6.23 102mmol/L$minute, respectiv
insulin glulisine than with regular insulin, but the difference was no
L$minute, respectively, P 5 .099).Of the remaining insulin reaching the systemic circulation,
30% to 80% is considered to be degraded by the kidney.11
The figures of renal insulin clearance are very rough esti-
mates. However, the contribution of the kidney to insulin
degradation is easily presumed to be much higher in patients
receiving exogenous insulin because subcutaneously injected
insulin doesnot directlyenter the portal circulation.11There-
fore, careful attention is needed in patients with diabetes and
severe renal insufficiency who are treated with insulin.
With advanced renal insufficiency, insulin requirement
gradually decreases,19 a situation often encountered in
clinical practice. Except reductions in the dose of insulin,se after breakfast (AUC-B 0-4), lunch (AUC-L 0-6), and dinner
isine treatment (Day 2). AUC-B 0-4 and AUC-D 0-6 were lower
vs. 6.2 6 5.4 3 102 mmol/L$minute, respectively, P 5 .028;
ely,P5 .023). In contrast, AUC-L 0-6 tended to be higher with
t significant (AUC-L 0-6: 7.6 6 6.4 vs. 4.2 6 8.7 3 102 mmol/
GLULISINE IN SEVERE RENAL INSUFFICIENCY 133rapid-acting insulin analogs may theoretically offer advan-
tages over regular insulin in patients with diabetes and renal
insufficiency because the incidence of hypoglycemia is lower
with their use. However, reports that have directly compared
these 2 insulin types under renal insufficiency are surprisingly
limited in spite of the prevailing issues in clinical practice.
Rave et al.20 quantified the pharmacokinetic and pharmaco-
dynamic properties of regular insulin and insulin lispro in pa-
tients with type 1 diabetes and without renal insufficiency
(average GFR: 54 and 90 mL/minute/1.73 m2, respec-
tively). As expected, the levels for regular insulin and insulin
lispro during the 8-hour period after injection were higher
in patients with renal insufficiency than in those without,
possibly reflecting reduction of insulin clearance in renal
insufficiency. Moreover, peak insulin levels were higher
and time to maximal insulin concentration was shorter after
subcutaneous insulin lispro injection than regular insulin in-
jection in patients with renal insufficiency. Interestingly, they
observed decreased hypoglycemic effect of regular insulin in
patients with renal insufficiency, but the reasons for this
remain unknown. On the other hand, insulin lispro main-
tains its properties even under such conditions, suggesting
that it is preferable because of its efficacy. Some characteris-
tics of insulin lispro, such as a faster onset of action, higher
peak insulin levels, and a shorter duration of action than reg-
ular insulin, were also confirmed in patients with diabetes on
hemodialysis.21 The findings of the previously mentioned
studies emphasize the effectiveness and safety of rapid-
acting insulin analogs in patients with diabetes and renal
insufficiency, based on the pharmacokinetics and pharmaco-
dynamics of one-shot injection of different insulin types. In
contrast, we investigated the effects of 3 daily injections of 2
insulin types on glycemic control using 24-hour monitoring
of BG levels using CGM, which may be a more relevant
approach if applied in daily medical practice.
Our results showed that insulin glulisine effectively sup-
pressedpostprandial hyperglycemia after breakfast anddinner,
as expected (Fig. 2). However, the AUC-L 0-6 tended to be
higher with insulin glulisine than with regular insulin. Previ-
ous reports showed that plasma concentrations of insulin lis-
pro returned to almost baseline levels within 4 hours of
injection in patients with diabetes and renal insufficiency,
whereas those of regular insulin were sustained at higher
levels.20 A previous study has shown that the nadir of BG
levelswas observed 3 hours after insulin lispro injection in he-
modialysis patients, althoughBG level suppressionwas higher
with regular insulin.21 So far, pharmacokinetic and pharma-
codynamic characteristics of insulin glulisine have not been
reported in patients with renal insufficiency. The pharmaco-
kinetics of the 3 types of rapid-acting insulin analogs are
generally similar to each other in subjectswithout renal insuf-
ficiency, with the exception that insulin glulisine has a slightly
faster onset of action than insulin lispro and insulin aspart.15,16
These reports suggest that insulin glulisine and insulin lispro
have a faster onset and a shorter duration of action inpatients with renal insufficiency, with insulin glulisine
having a slight advantage. Because the interval between
breakfast and lunch was 4 hours in the present study, the
hypoglycemic effects of regular insulin injected at breakfast
might have persisted even after lunch. On the basis of the
observation that regular insulin concentrations returned to
baseline after 5 or 6 hours,20 regular insulin injected at lunch
could not have affected glycemic changes after dinner.
The present study has several limitations. First, this was
not a crossover design study, and it involved a relatively
small number of patients. However, if we performed the
reversal analysis after titration with insulin glulisine, harm-
ful hypoglycemia induced by regular insulin may have
occurred, especially after lunch. Second, we did not exam-
ined insulin concentrations after regular insulin or insulin
glulisine injections. Third, severe hypoglycemic episodes
were not observed in this study. One reason should be
that insulin titration might not have been enough to avoid
hypoglycemia. Indeed, average BG levels before and after
each meal did not reach target ranges. Another reason
might be that residual endogenous insulin could achieve a
favorable result because all participating patients had type
2 diabetes and not type 1 diabetes.
In conclusion, we have shown that compared with reg-
ular insulin, the efficacy and safety of the rapid-acting insu-
lin analog, insulin glulisine, is high in patients with diabetes
and severe renal insufficiency. We conclude that rapid-
acting insulin can improve glycemic control with a
decreased risk of life-threatening hypoglycemia in patients
with diabetes and severe renal insufficiency.
Practical Application
Insulin is recommended to control hyperglycemia in dia-
betic patients with severe renal insufficiency. However, it is
unclear what kind of insulin is better. We found that rapid-
acting insulin glulisine improved glycemic control with a
decreased risk of hypoglycemia compared with regular
insulin under conditions of severe renal insufficiency.
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